+149.1%
GDX vs MRNA
-16.0%
+165.0%
-46.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | -3.9% | +4.7% | +1.1% |
| 7D | -8.0% | -17.6% | +9.6% | -6.6% |
| 30D | -9.3% | -5.1% | -4.1% | -9.0% |
| 3M | -13.4% | +220.8% | -234.2% | -25.3% |
| 6M | -8.9% | +321.7% | -330.6% | -23.8% |
| YTD | -7.2% | +601.3% | -608.5% | -25.9% |
| 1Y | +6.9% | +735.2% | -728.3% | -15.9% |
| 3Y | +189.9% | +170.5% | +19.4% | +140.9% |
| All | +149.1% | -16.0% | +165.0% | +119.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling